EI
FSTX

EAM Investors’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

EAM Investors’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,666
Closed -$718K – 367
2017
Q3 		$718K Hold
10,666
– – 0.1% 249
2017
Q2 		$578K Buy
+10,666
New +$494K 0.1% 252

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

EAM Investors's FSTX Position: Q4 2017 in Review

EAM Investors sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2017, closing a stake of 10,666 shares — an estimated $718K sold.

EAM Investors first reported a position in FSTX in Q2 2017 and held it in 2 quarters. The position peaked at $718K in Q3 2017. 38 funds tracked by Wall St. Rank hold FSTX as of Q4 2017.

  • EAM Investors reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • EAM Investors sold 10,666 F-star Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $718K.
  • EAM Investors first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • EAM Investors's F-star Therapeutics, Inc. Common Stock position peaked at $718K in Q3 2017.
  • 38 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.